• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds 1,2-diols

Research Brief on DL-2,3-Butanediol (CAS: 6982-25-8): Recent Advances and Applications in Chemical Biomedicine

DL-2,3-Butanediol (CAS: 6982-25-8) is a versatile chiral diol with significant applications in chemical biomedicine, particularly in drug synthesis, biocatalysis, and biopolymer production. Recent studies have highlighted its potential as a platform chemical for sustainable pharmaceutical manufacturing. This brief synthesizes key findings from 2023-2024 literature, focusing on microbial production optimization, stereoselective applications, and novel therapeutic derivatives.

A breakthrough study published in Nature Catalysis (2023) demonstrated a 72% yield improvement in DL-2,3-butanediol production via engineered Bacillus subtilis strains using CRISPR-Cas9 mediated pathway optimization. The research identified key rate-limiting enzymes (acetolactate synthase and butanediol dehydrogenase) whose overexpression increased titer to 128 g/L in fed-batch fermentation. Notably, the team achieved 98% optical purity of the D-(-) enantiomer, crucial for pharmaceutical applications requiring specific stereochemistry.

In pharmaceutical chemistry, DL-2,3-butanediol serves as a precursor for antitumor agents. A 2024 Journal of Medicinal Chemistry paper reported novel platinum(II) complexes incorporating butanediol-derived ligands showing 3-5× enhanced cytotoxicity against cisplatin-resistant ovarian cancer cell lines (A2780/CP70). The CAS: 6982-25-8 derivative exhibited unique DNA intercalation properties confirmed by X-ray crystallography and molecular dynamics simulations.

Metabolic engineering advances have enabled the production of chiral butanediol derivatives for neurologic applications. Researchers at MIT developed a chemoenzymatic cascade converting DL-2,3-butanediol to (R)-3-hydroxybutyrate, a potential neuroprotective agent. The process achieved 91% enantiomeric excess using a novel NADPH-dependent reductase (Patent WO2024011123). This addresses previous challenges in producing pharmaceutically relevant enantiomers from racemic mixtures.

Quality control methodologies have also evolved. A 2023 Analytical Chemistry study validated a UPLC-MS/MS method for detecting DL-2,3-butanediol impurities (LOQ: 0.1 ppm) in parenteral formulations. The method resolved critical isomeric impurities like meso-2,3-butanediol that affect drug safety profiles. This supports compliance with ICH Q3D guidelines for elemental impurities in pharmaceutical-grade butanediol.

Emerging applications include its use as a cryoprotectant in mRNA vaccine stabilization. Pfizer's recent preprint demonstrated DL-2,3-butanediol's superiority over sucrose in maintaining lipid nanoparticle integrity at -20°C, with 98% mRNA recovery after 6-month storage. The mechanism involves unique hydrogen-bonding patterns with phosphate groups, as revealed by neutron scattering studies.

Despite these advances, challenges remain in large-scale GMP production. A 2024 industry white paper highlighted regulatory concerns about residual host cell proteins in microbial-derived butanediol, prompting development of new affinity chromatography purification methods. Ongoing Phase III trials of butanediol-derived immunosuppressants (e.g., BTN-3267) will likely shape future quality standards.

In conclusion, DL-2,3-butanediol (6982-25-8) continues to demonstrate expanding utility in precision medicine and sustainable pharma manufacturing. Future research directions should focus on continuous bioprocessing, enantiomer-specific pharmacokinetics, and green chemistry applications to fully realize its potential as a multifunctional pharmaceutical building block.

• 5341-95-7(2,3-Butanediol,(2R,3S)-rel-)
• 73522-17-5((S)-Butane-1,2-diol)
• 584-03-2(1,2-Butanediol)
• 14898-79-4((R)-(-)-2-Butanol)
• 40348-66-1((R)-Butane-1,2-diol)
• 4221-99-2((+)-2-Butanol)
• 513-85-9(2,3-Butanediol)
• 26171-83-5(1,2-Butanediol)
• 15892-23-6(2-butanol, (±)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)